Repository logo
 
Publication

The Use of Statins in People at Risk of Developing Diabetes Mellitus: Evidence and Guidance for Clinical Practice

2014Journal article Open access
Simple item page
dc.contributor.authorSattar, N
dc.contributor.authorGinsberg, H
dc.contributor.authorRay, K
dc.contributor.authorChapman, MJ
dc.contributor.authorArca, M
dc.contributor.authorAverna, M
dc.contributor.authorBetteridge, DJ
dc.contributor.authorBhatnagar, D
dc.contributor.authorBilianou, E
dc.contributor.authorCarmena, R
dc.contributor.authorCeska, R
dc.contributor.authorCorsini, A
dc.contributor.authorErbel, R
dc.contributor.authorFlynn, P
dc.contributor.authorGarcia-Moll, X
dc.contributor.authorGumprecht, J
dc.contributor.authorIshibashi, S
dc.contributor.authorJambart, S
dc.contributor.authorKastelein, J
dc.contributor.authorMaher, V
dc.contributor.authorMarques da Silva, P
dc.contributor.authorMasana, L
dc.contributor.authorOdawara, M
dc.contributor.authorPedersen, T
dc.contributor.authorRotella, CM
dc.contributor.authorSalti, I
dc.contributor.authorTeramoto, T
dc.contributor.authorTokgozoglu, L
dc.contributor.authorToth, P
dc.contributor.authorValensi, P
dc.contributor.authorVergès, B
dc.date.accessioned2015-04-24T10:42:42Z
dc.date.available2015-04-24T10:42:42Z
dc.date.issued2014
dc.description.abstractReducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these claims and provides practical guidance for primary care physicians on the use of statins in people with or at risk of developing T2D. Overall, evidence suggests that the benefits of statins for the reduction of CV risk far outweigh the risk of developing T2D, especially in individuals with higher CV risk. To reduce the risk of developing T2D, physicians should assess all patients for T2D risk prior to starting statin therapy, educate patients about their risks, and encourage risk-reduction through lifestyle changes. Whether some statins are more diabetogenic than others requires further study. Statin-treated patients at high risk of developing T2D should regularly be monitored for changes in blood glucose or HbA1c levels, and the risk of conversion from pre-diabetes to T2D should be reduced by intensifying lifestyle changes. Should a patient develop T2D during statin treatment, physicians should continue with statin therapy and manage T2D in accordance with relevant national guidelines.por
dc.identifier.citationAtheroscler Suppl. 2014 Jun;15(1):1-15por
dc.identifier.urihttp://hdl.handle.net/10400.17/2133
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherElsevierpor
dc.subjectHSM MEDpor
dc.subjectAnticholesteremic Agents/administration & dosagepor
dc.subjectAnticholesteremic Agents/adverse effectspor
dc.subjectAnticholesteremic Agents/pharmacologypor
dc.subjectAnticholesteremic Agents/therapeutic usepor
dc.subjectCardiovascular Diseases/epidemiologypor
dc.subjectCardiovascular Diseases/prevention & control
dc.subjectCholesterol, LDL/blood
dc.subjectCohort Studies
dc.subjectComorbidity
dc.subjectDiabetes Mellitus, Type 2/epidemiology
dc.subjectDiabetes Mellitus, Type 2/etiology
dc.subjectDiabetes Mellitus, Type 2/prevention & control
dc.subjectDisease Susceptibility
dc.subjectFasting/blood
dc.subjectForecasting
dc.subjectHemoglobin A, Glycosylated/analysis
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
dc.subjectMeta-Analysis as Topic
dc.subjectMulticenter Studies as Topic/statistics & numerical data
dc.subjectObservational Study as Topic
dc.subjectPractice Guidelines as Topic
dc.subjectPrediabetic State/epidemiology
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.titleThe Use of Statins in People at Risk of Developing Diabetes Mellitus: Evidence and Guidance for Clinical Practicepor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage15por
oaire.citation.startPage1por
oaire.citation.titleAtherosclerosis. Supplementspor
rcaap.rightsopenAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Atherosclerosis Sup 2014.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

MED - Artigos